Human melanoma A2058 and A375 cells harbor the tumor-driving BRAF(V600E) mutation, which is present in approximately 50% of human melanomas [4,5] and represents a major target in melanoma therapy [66]. This evidence concerns the gene BRAF and neoplasm.